Stock screener

JUNS

Conviction 67HealthcareScan · Tue, Sep 8, 2026
JUNS$3.11-5.18%
ResistanceSupportVol 14
63 bars
Vol MA14 3.88M
Jun 9Jun 26Jul 16Aug 3Aug 20Sep 8
JUPITER NEUROSCIENCES, INC.Pharmaceutical Preparationswww.jupiterneurosciences.com
Price3.11
Change-5.18%
Gap-2.44%
Rel volume0.02×
Avg volume2.74M
Avg $ vol16.84M
SMA 204.59
SMA 502.13
SMA 2000.9832
Price vs 50+45.79%
Price vs 200+216.33%
MA stackbullish
50/200 cross
Supertrenddown · 5.28
RSI (14)46
MACD hist-0.39
MACD crossbear · 7d
Stoch %K / %D3 / 4
ADX (14)49
+DI / −DI45 / 22
RSI divergenceBearish
MACD divergenceBearish
ATR %+22.49%
ADR %16.32%
52w high6.20
52w low0.0751
From 52w high-49.84%
Above 52w low+4041.15%
New 52w highNo
SqueezeOff
Bollinger width81.58%
%B0.10
Donchian pos2.76%
Donchian high11.20
Donchian low2.88
AVWAP (52w high)7.53
vs AVWAP high-58.72%
AVWAP (52w low)6.54
vs AVWAP low-52.44%
OBV trendUp
Chaikin MF (20)-0.72
Today vs 20d0.02×
Avg vol (14d)3.88M
Avg vol (20d)2.74M
Avg $ vol (20d)16.84M
Market cap2.39M
RS 3m (vs SPY)+1250.39%
RS 6m (vs SPY)+733.00%
RS line new highNo
Trend template5/8
Technical rank76.1
1 week-12.15%
1 month-39.02%
3 months+1246.32%
6 months+633.14%
1 year+152.85%
YTD+207.92%
P/E-0.28
P/B-6.54
P/S109.88
P/FCF
EPS-0.2500
Div yield
ROE
ROA-232.48%
Debt/Eq
Current0.66
EV/EBITDA
Gross margin80.59%
Net margin
Rev growth
EPS growth-254.35%
Price target
Target upside
Analyst rating
Institutional1.64%
Ent. value2.39M
Revenue24.25K
Net income-2.27M
Gross profit21.06K
Free cash flow
IndustryPharmaceutical Preparations
ExchangeNasdaq
Shares out36.28M
Employees5
ListedTue, Dec 3, 2024
Free float7.35M
Float %21.4%
Short interest29.68K
Days to cover0.3d
Short volume42.2%
Squeeze score4 / 100
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeB
Conviction67 / 100
Pattern quality
Tech rank76.1 / 100
Group rank
Status laneNo active setup
Setup direction
Pattern family
Resistance8.65
Support0.0771
Days since event
Candle confirm
News sentiment

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in JUNS

All disclosures →
No recent disclosed trades by Congress in JUNS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in JUNS · 5 buys · 5 sells

InsiderSideShares
Cutler Andrew Jon
Director · Stock Option (right to buy) · 2026-07-31
Grant472.22K
Hayward Marshall A.
Chief Scientific Officer · Common Stock · 2026-03-02
Exercise225K
Hayward Marshall A.
Chief Scientific Officer · Stock Option (right to buy) · 2026-03-02
Exercise225K
Hayward Marshall A.
Chief Scientific Officer · Restricted Stock Units · 2025-06-02
Exercise389.79K
Hayward Marshall A.
Chief Scientific Officer · Restricted Stock Award · 2025-06-02
Exercise399.4K
Hemmerly Nicholas H.
Director · Common Stock · 2025-06-02
Exercise95.55K
Hemmerly Nicholas H.
Director · Restricted Stock Units · 2025-06-02
Exercise95.55K
Weis Holger
Director · Common Stock · 2025-06-02
Exercise85.8K
Weis Holger
Director · Restricted Stock Units · 2025-06-02
Exercise85.8K
Rosen Alexander Gustaf Erik
Chief Administrative Officer · Common Stock · 2025-06-02
Exercise164.55K

SEC filings

EDGAR filings in JUNS · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.